CA2275708A1 - Diagnostic et traitement de grossesses pathologiques - Google Patents

Diagnostic et traitement de grossesses pathologiques Download PDF

Info

Publication number
CA2275708A1
CA2275708A1 CA002275708A CA2275708A CA2275708A1 CA 2275708 A1 CA2275708 A1 CA 2275708A1 CA 002275708 A CA002275708 A CA 002275708A CA 2275708 A CA2275708 A CA 2275708A CA 2275708 A1 CA2275708 A1 CA 2275708A1
Authority
CA
Canada
Prior art keywords
vegf
amount
therapeutic substance
woman
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002275708A
Other languages
English (en)
Inventor
David Stephen Charnock-Jones
Stephen Kevin Smith
Dawn Elizabeth Clark
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cambridge University Technical Services Ltd CUTS
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9626702.6A external-priority patent/GB9626702D0/en
Application filed by Individual filed Critical Individual
Publication of CA2275708A1 publication Critical patent/CA2275708A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1891—Angiogenesic factors; Angiogenin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/321—Arterial hypertension

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Vascular Medicine (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

L'invention concerne une méthode de traitement d'un trouble hypertensif chez une femme enceinte, la méthode consistant à administrer à la femme enceinte une dose d'une substance thérapeutique régulant la quantité et/ou l'activité du facteur de croissance endothéliale vasculaire chez la femme enceinte, la quantité de substance administrée étant efficace pour traiter le trouble hypertensif. L'invention concerne également des méthodes des kits et diagnostiques.
CA002275708A 1996-12-23 1997-12-22 Diagnostic et traitement de grossesses pathologiques Abandoned CA2275708A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB9626702.6 1996-12-23
GBGB9626702.6A GB9626702D0 (en) 1996-12-23 1996-12-23 Diagnosis and treatment of pathological pregnancies
US5705597P 1997-08-27 1997-08-27
US60/057,055 1997-08-27
PCT/GB1997/003519 WO1998028006A1 (fr) 1996-12-23 1997-12-22 Diagnostic et traitement de grossesses pathologiques

Publications (1)

Publication Number Publication Date
CA2275708A1 true CA2275708A1 (fr) 1998-07-02

Family

ID=26310711

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002275708A Abandoned CA2275708A1 (fr) 1996-12-23 1997-12-22 Diagnostic et traitement de grossesses pathologiques

Country Status (4)

Country Link
EP (1) EP0951298A1 (fr)
AU (1) AU5331298A (fr)
CA (1) CA2275708A1 (fr)
WO (1) WO1998028006A1 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9812432D0 (en) * 1998-06-09 1998-08-05 Queen Mary & Westfield College Predictive test
US7030083B2 (en) 1998-09-09 2006-04-18 University Of Washington Treatment of eclampsia and preeclampsia
EP1417971A3 (fr) * 1998-09-09 2004-06-30 Scios Inc. Utilisation d' un facteur angiogénique pour le traitement d'angiopathies microvasculaires
GB0008269D0 (en) 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
GB0026823D0 (en) * 2000-11-02 2000-12-20 King S College London Diagnosis of pre-eclampsia
US7435419B2 (en) 2002-07-19 2008-10-14 Beth Israel Deaconess Medical Center Methods of diagnosing and treating pre-eclampsia or eclampsia
CA2496253C (fr) * 2002-07-19 2016-05-10 Beth Israel Deaconess Medical Center, Inc. Procedes de diagnostic et de traitement de pre-eclampsie ou d'eclampsie
US7335362B2 (en) 2002-07-19 2008-02-26 Beth Israel Deaconess Medical Center Methods of treating pre-eclampsia or eclampsia
EP1561116B9 (fr) 2002-11-16 2009-04-01 Siemens Healthcare Diagnostics Products GmbH Scd40l et facteur de croissance placentaire (pigf) servant de combinaisons de marqueurs biochimiques pour des maladies cardiovasculaires
EP1664797B1 (fr) 2003-09-23 2015-11-11 The General Hospital Corporation Criblage destine a pré-éclampsie
JP2007536251A (ja) 2004-05-04 2007-12-13 チルドレンズ メディカル センター コーポレーション 子癇前症の処置のための方法および組成物
US7740849B2 (en) 2004-09-24 2010-06-22 Beth Israel Deaconess Medical Center Use of compounds that bind soluble endoglin and SFLT-1 for the treatment of pregnancy related hypertensive disorders
DK1804836T3 (da) 2004-09-24 2011-01-24 Beth Israel Hospital Fremgangsmåder til diagnosticering og behandling af graviditetskomplikationer
DE102004051847B4 (de) 2004-10-25 2008-09-18 Dade Behring Marburg Gmbh Verhältnis von PIGF und Flt-1 als prognostischer Parameter bei kardio-vaskulären Erkrankungen
DE602005023216D1 (de) 2004-12-15 2010-10-07 Beth Israel Hospital Nukleinsäuren und polypeptide zur diagnose und behandlung von schwangerschaftskomplikationen
EP1839056B1 (fr) * 2004-12-21 2011-08-03 Yale University Diagnostic de la preeclampsie
MX2008001966A (es) * 2005-08-12 2008-03-26 Regeneron Pharma Tratamiento de enfermedades mediante administracion subcutanea de un antagonista vegf.
EP1929295A4 (fr) * 2005-08-30 2010-03-17 Biosite Inc Utilisation de flt-1 soluble et de ses fragments dans des etats cardio-vasculaires
GB0600916D0 (en) 2006-01-17 2006-02-22 Perkinelmer Instr Las Inc detecting and predicting pre-eclampsia
CN107677828A (zh) 2008-10-31 2018-02-09 耶鲁大学 子痫前期检测和治疗的方法和组合物
CA3157573A1 (fr) 2014-04-10 2015-10-15 Yale University Procedes et compositions de detection de proteines mal repliees
EP4070113A4 (fr) 2019-12-04 2023-12-20 Biora Therapeutics, Inc. Évaluation de la prééclampsie à l'aide de dosages du facteur de croissance placentaire libre et dissocié

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU687727B2 (en) * 1992-10-28 1998-03-05 Genentech Inc. Vascular endothelial cell growth factor antagonists
GB9410534D0 (en) * 1994-05-26 1994-07-13 Lynxvale Ltd Improvements in or relating to growth factor inhibitors

Also Published As

Publication number Publication date
AU5331298A (en) 1998-07-17
WO1998028006A1 (fr) 1998-07-02
EP0951298A1 (fr) 1999-10-27

Similar Documents

Publication Publication Date Title
CA2275708A1 (fr) Diagnostic et traitement de grossesses pathologiques
EP1054687B1 (fr) Vecteurs d'expression et lignees cellulaires exprimant le facteur de croissance endothelial vasculaire d, et procede de traitement des melanomes
US6730489B1 (en) Antibodies to truncated VEGF-D and uses thereof
Clark et al. Localization of VEGF and expression of its receptors flit and KDR in human placenta throughout pregnancy
JP3275024B2 (ja) 血管内皮増殖因子−ｂ
CA2063431C (fr) Recepteurs de facteurs de croisance fibroblastes
US20070042413A1 (en) Platelet-derived growth factor D, DNA coding therefor, and uses thereof
JP2003508009A (ja) 新規なニューロピリン／増殖因子結合及びその利用法
JP2003515313A (ja) 組換え血小板コラーゲン受容体糖タンパク質ｖｉおよびその薬学的使用
JP2010512781A (ja) Ｖｅｇｆｒの変化体ならびに妊娠関連の医学的状態の診断および処置におけるその使用
JP2000516478A (ja) Ｖｅｇｆ−ｂ／受容体複合体およびその利用方法
US20050250103A1 (en) Methods for detecting for the presence of tumor cells and for screening for anti-tumor agents
AU765888B2 (en) Expression vectors and cell lines expressing vascular endothelial growth factor D, and method of treating melanomas

Legal Events

Date Code Title Description
FZDE Discontinued